Patients with AD and comorbid ARC under therapy with a monoclonal anti‐IL‐4Rα antibody (index group) or receiving an AIT (control group) were, herein, studied to investigate how the monoclonal anti‐IL‐4Rα antibody impacts the total IgE and the sIgE levels as well as the allergen‐specific basophil activation and T cell proliferation. Here, IGHE is linked to Alzheimer disease.